Foundation Medicine Teams Up with Pharma to Advance Personalized Oncology | GenomeWeb

Cancer diagnostics company Foundation Medicine has signed deals with four pharmaceutical companies this year, allowing those companies to use its clinical cancer genomic test. In early 2011, Foundation inked deals with Novartis, Celgene, and an undisclosed company, and it recently signed a similar deal with Johnson & Johnson Pharmaceutical Research and Development. Foundation Medicine's test uses next-generation sequencing to analyze small formalin-fixed, paraffin-embedded tumor samples, and checks for mutations in more than 200 cancer-related genes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.